SIRT1-IN-1 is a selective inhibitor of SIRT1 with an IC50 of 205 nM. SIRT1-IN-1 is an inhibitor of cytomegalovirus (CMV) with antiviral activity.

Sirt2-IN-1 is an inhibitor of sirtuin 2 (IC50 = 163 nM).

SIRT1 Activator 1 (Compound 3), a marine-derived xyloallenoide A derivative from the Xylaria sp. mangrove fungus, exhibits angiogenic effects in zebrafish and protects human endothelial progenitor cells (hEPCs) from AngII-induced senescence. It achieves this by elevating SIRT1 expression and modulating the AMPK/Akt signaling pathway [1].

HSP70/SIRT2-IN-1 (Compound 2a) serves as a dual inhibitor targeting both SIRT2 and HSP70, exhibiting an IC50 of 17.3±2.0 μM against SIRT2. This compound possesses antitumor activity [1].

SIRT-IN-1 is a potent SIRT1/2/3 inhibitor(IC50s of 15, 10, 33 μM, respectively).

Sirt1/2-IN-2 (compound hsa55) serves as a dual inhibitor for SIRT1 with an IC50 of 1.8 μM and SIRT2 with an IC50 of 2.4 μM, respectively. It effectively inhibits p53 deacetylation while enhancing the acetylation of p53 and α-tubulin. The compound also promotes apoptosis and exhibits anti-proliferative effects on human leukemia cell lines [1].

Sirt1/2-IN-4 (compound PS3) is a potent triple inhibitor of SIRT1, SIRT2, and SIRT3, exhibiting IC50 values of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respectively. It effectively inhibits p53 deacetylation, indicating potential anticancer properties [1].

SIRT1/2/3-IN-1 (compound 10) is a potent, selective, and cell-permeable inhibitor targeting SIRT1, SIRT2, and SIRT3, demonstrating inhibitory concentrations (IC50s) of 0.54 μM, 0.253 μM, and 0.72 μM, respectively. It is utilized in cancer research [1].

Sirt1/2-IN-3 (compound PS9) serves as a dual inhibitor of SIRT1/2, exhibiting IC50 values of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respectively. This compound effectively inhibits p53 deacetylation while simultaneously elevating p53 and α-tubulin acetylation levels. Additionally, Sirt1/2-IN-3 promotes apoptosis and exhibits antiproliferative effects on human leukemia cell lines [1].

SIRT1-IN-3 (compound 3j) is a potent and selective inhibitor of silent information regulator 1 (SIRT1) with an IC 50 of 4.2 μM [1].

Sirt1/2-IN-1 (Compound 7) is an inhibitor of SIRT1 and SIRT2 and is capable of acting on SIRT1 (IC50: 1.81 μg/mL), SIRT2 (IC50: 2.10 μg/mL) and SIRT3 (IC50: 20.5 μg/mL) and has α-microtubulin hyperacetylation activity ( Sirt1/2-IN-1 exhibited significant anticancer effects.

SIRT1-IN-2 (compound 3h) is a potent and selective inhibitor of SIRT1 (silent information regulator 1) with an IC 50 of 1.6 μM [1].

SIRT6-IN-1, a novel SIRT6 inhibitor, reduces glycemia and improves oral glucose tolerance in unfed wild-type mice.

SIRT-IN-2 is a potent SIRT1/2/3 inhibitor(IC50s of 4, 1, 7 μM, respectively).

SIRT-IN-3, a potent inhibitor of SIRT1 with an IC50 value of 17 μM, exhibits approximate 4-fold and 14-fold greater selectivity for SIRT1 over SIRT2 and SIRT3, with respective IC50 values of 74 μM for SIRT2 and 235 μM for SIRT3 [1].

Decapeptide-12, a competitive inhibitor of mushroom tyrosinase with an IC50 of 40 µM and a Kd of 61.1 μM for the C-terminal residue of tyrosinase, is a small oligopeptide that reduces melanin content in melanocytes by interacting with tyrosinase and increasing transcription of SIRT. It is utilized in researching melanogenesis, senescence, and inflammation [1] [2] [3].